Humira Pen Crohn's-Uc-Hs(Adalimumab)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$2.7M
Medicare cost, 2023
$2.7M
Medicare cost, 2023
Medicare drug plans spent on Humira Pen Crohn's-Uc-Hs (adalimumab) in 2024, for prescriptions and refills. Spending fell 42% from 2022 to 2023.
Medicare cost, 2023
$2.7M
-41.6% from 2022
Prescriptions
137
$19,714.04 per claim
Patients
117
113 prescribers
Total spending
-
All plans
Questions and answers
How much does Medicare spend on Humira Pen Crohn's-Uc-Hs?
Medicare prescription drug plans paid $2.7M for Humira Pen Crohn's-Uc-Hs in 2023, for 137 prescriptions and refills to 117 patients (down 41.6% from 2022). The average cost per claim was $19,714.04.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 202 | 255 | 209 | $4.6M |
| 2023 | 113 | 137 | 117 | $2.7M |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 716,864 side-effect reports named adalimumab, the active ingredient of Humira Pen Crohn's-Uc-Hs (reports from 1993 on). 367,566 of them (51.3%) were serious, 31,605 named a death and 152,383 named a hospital stay. The reactions named most often were drug ineffective, pain and arthralgia. 187,721 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
716,864
23,258 in 2025 (-20.8% from 2024)
Serious
51.3%
367,566 reports
Deaths named
31,605
4.4% of reports
Hospital stays
152,383
21.3% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
Since 2002. 2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Humira Pen Crohn's-Uc-Hs?
716,864 reports from 1993 through September 2026 named adalimumab, the active ingredient of Humira Pen Crohn's-Uc-Hs. 367,566 of them (51.3%) were serious, 31,605 named a death and 152,383 named a hospital stay.
What are the most reported side effects of Humira Pen Crohn's-Uc-Hs?
92,932 reports named drug ineffective, the reaction named most often, followed by pain (50,798) and arthralgia (49,681). In the last 5 years the reaction named most often was drug ineffective (22,775 reports). A report can name several reactions.
How many side-effect reports named Humira Pen Crohn's-Uc-Hs in 2025?
23,258 reports were received in 2025 (-20.8% from 2024). 2026 so far: 12,817 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Humira Pen Crohn's-Uc-Hs caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Humira Pen Crohn's-Uc-Hs caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with adalimumab: Humira(Cf) Pen, Humira Pen, Humira(Cf), Humira, Humira(Cf) Pen Crohn's-Uc-Hs, Humira(Cf) Pen Psor-Uv-Adol Hs, Humira Pen Psor-Uveits-Adol Hs, Humira(Cf) Pediatric Crohn's
- Makers on the stock market:
ABBV·ABBV drug pipeline - Drug approvals (1 approval on file for adalimumab) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (adalimumab) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.